IPO - AIM ImmunoTech Inc.

Form Type: S-1

Filing Date: 2025-01-23

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003444

Filing Summary: AIM ImmunoTech Inc. filed an S-1 registration statement for an initial public offering (IPO), indicating the company's intention to raise capital through the public markets. The document includes detailed financial information covering revenue, expenses, and projections for future growth, reflecting the business operations that underline AIM's product pipeline and strategic objectives. The company highlights collaboration efforts and potential partnerships to enhance market reach and product development. Significant notes on preferred and common stock are also addressed, detailing share structure and incentives for investors. AIM ImmunoTech positions itself to capitalize on advancements in biotechnology focused on immunotherapeutic treatments, with specific emphasis on developing their lead compound, Ampligen. This filing outlines the anticipated use of proceeds from the offering to support ongoing clinical trials and operational activities necessary for business expansion.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-11-15

Corporate Action: Ipo

Type: New

Accession Number: 000149315224046307

Filing Summary: AIM ImmunoTech Inc. has submitted a registration statement on Form S-1 to the U.S. Securities and Exchange Commission as part of their initial public offering process. The document outlines the filing details and provides contact information for inquiries regarding the registration. Richard Feiner of Silverman Shin & Schneider PLLC is the representative for the filing, while Peter W Rodino III serves as the main contact for AIM. This document signifies a new step for AIM towards entering public trading, facilitating the company’s capital raising efforts.

Document Link: View Document